A study evaluating efficacy of cabazitaxel in patient with castration resistant prostate cancer.

Trial Profile

A study evaluating efficacy of cabazitaxel in patient with castration resistant prostate cancer.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Cabazitaxel (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 11 Oct 2017 New trial record
    • 12 Sep 2017 Results assessing prognostic role for circulating tumor cells (CTCs) in castration resistant prostate cancer patient treated with cabazitaxel, were presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top